About Veracyte
Veracyte is a publicly listed company based in San Francisco (United States) founded in 2008. Genomics-based diagnostic tests for cancer are developed. Veracyte has raised $67.9 million across 6 funding rounds from investors including Kleiner Perkins, TPG and General Electric. The company has 824 employees. Veracyte has completed 4 acquisitions, including Allegro Diagnostics, C2i Genomics and Decipher. Its website veracyte.com draws about 54 thousand monthly visits. Veracyte offers products and services including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Genetic Testing. Its legal entity is Veracyte, Inc. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
Veracyte was founded in 2008 and is headquartered in San Francisco, United States. Genomics-based diagnostics for cancer are developed and offered by the company within the healthcare sector. Products such as the Percepta test are utilized to evaluate lung cancer risk through analysis of bronchial epithelial cells, while the Afirma Thyroid FNA Analysis identifies benign thyroid nodules. Additional tests, including the Envisia classifier for idiopathic pulmonary fibrosis, are under development.
- Headquarters San Francisco, United States
- Employees 824
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website veracyte.com
- Social LinkedIn X YouTube
- Legal Name Veracyte, Inc.
- Annual Revenue$517.14 M (USD)16.01as on Dec 31, 2025
- Net Profit$66.35 M (USD)174.89as on Dec 31, 2025
- EBITDA$114.99 M (USD)102.91as on Dec 31, 2025
- Total Equity Funding$67.9M (USD)
in 6 rounds
- Latest Funding Round$45M (USD), Debt – Conventional
Mar 2016
- InvestorsKleiner Perkins
& 9 more
- Employee Count824
- Investments & AcquisitionsAllegro Diagnostics
& 3 more
Products & Services of Veracyte
Veracyte offers a comprehensive portfolio of products and services, including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier.
Test for thyroid cancer diagnosis using genomic data.
Assists in prostate cancer prognosis and treatment decisions.
Evaluates breast cancer risk through genomic analysis.
Supports bladder cancer assessment with molecular insights.
Apps and channels of Veracyte
its YouTube channel Veracyte has 607 subscribers and 30 videos.
Videos from Veracyte
The most watched videos on Veracyte's YouTube channel, Veracyte (607 subscribers). Click a video to play it here.
More on Veracyte.
Funding Insights of Veracyte
Veracyte has successfully raised a total of $67.9M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $45 million completed in March 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.9M
- Total Rounds 6
- Last Round Debt – Conventional — $45M
- First Round $11.9M
(Jun 2008)
- Investors Count 10
All 6 funding rounds of Veracyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2016 | $45M | Debt – Conventional | – | – | – |
| Apr 2015 | $40M | Post-IPO | – | – | |
| Sep 2014 | $12.8M | Post-IPO | – | – | – |
| Jun 2013 | $28M | Series C | – | General Electric | |
| Jun 2010 | $28M | Series B | – | Domain Associates | |
| Jun 2008 | $11.9M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in Veracyte
Veracyte has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, TPG and General Electric.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
| longwoodcapitalpartners.com | ||||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Provides investment management and capital services for clients. | 2006 | cambercapital.com | Boston, United States | |
Diversified operations are conducted across multiple industries worldwide. | 1892 | ge.com | United States |
Investor details for Veracyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Veracyte
179 people are tracked at Veracyte (65 in leadership, 8 in board & advisors, 106 in team); the tracked headcount is 824.
| Name | Role | Group |
|---|---|---|
Ryan Ulaszek | Senior Director, Cloud Architecture | Leadership |
Brad Meyer | Director Of Automation & Process Engineering | Leadership |
John Leite | Chief Commercial Officer | Leadership |
Paul Schock | Director Cloud Devops | Leadership |
Natalia de la Fuente | Associate Director Medical Affairs | Leadership |
Bryan Coon | Vice President, Global Digital Transformation | Leadership |
Jeremy Adams | Director - PMO | Leadership |
Christelle Lautard | Associate Director Continuous Improvement And Compliance | Leadership |
Jerome van Crayelynghe | Director, Supply Chain | Leadership |
Carlo Artieri | Executive Director Of Bioinformatics And Data Science | Leadership |
Brian Niemeyer | Director, Cloud Architecture | Leadership |
Bill Moore | Vice President, Global IT Operations | Leadership |
Roy Coren | Chief Information Security Officer | Leadership |
Irina Rosca | Executive Director Supply Chain And Operations | Leadership |
Oanh Dang | Senior Director, Corporate And Business Development | Leadership |
Timothy Barr | Director Of Market Access | Leadership |
Brad Lotterman Apr | Director Of Communications | Leadership |
Steve Place | Director, Global Marketing Operations | Leadership |
Graham Poage | Director, Market Access | Leadership |
Norah Garrett | Director, Total Rewards | Leadership |
159 more people are available in the full profile.
Complete people profiles for Veracyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Veracyte
Veracyte is a publicly listed company on the NASDAQ with ticker symbol VCYT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Oct 2013
- Listed onNASDAQ: VCYT
- Listed entityVeracyte, Inc.
- Exchange sectorHealth technology
- ISINUS92337F1075
- Share price$43.11 (-2.07% on the day) · 2026-10-13
- Market capitalisation$3.47B
- Price to earnings30.6
- EPS (diluted, trailing year)$1.41
- Volume (last session)760,422
Financials of Veracyte
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $517.1M | $66.3M | $115.0M |
| 2024 | $445.8M | $24.1M | $56.7M |
| 2023 | $361.1M | -$74.4M | $15.1M |
| 2022 | $296.5M | -$36.6M | -$8.4M |
| 2021 | $219.5M | -$75.6M | -$37.8M |
Detailed financial statements for Veracyte
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Veracyte
Veracyte has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Allegro Diagnostics, C2i Genomics and Decipher.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Liquid biopsy for post-cancer surgery tumor monitoring is provided. | c2i-genomics.com | New York, United States | 2019 | Jan 2024 | $70M | |
Developer of diagnostic product for colon cancer | haliodx.com | Marseille, France | 2015 | Jun 2021 | •••• | |
Genomic test solutions for cancer diagnosis are developed. | decipherbio.com | San Diego, United States | 2008 | Feb 2021 | $600M | |
Genomic tests for lung cancer using next-generation sequencing were developed. | allegrodx.com | Maynard, United States | 2006 | Sep 2014 | $21M |
Complete acquisition details for Veracyte
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Veracyte
8 dated milestones of Veracyte across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Veracyte is founded.
- Funding First funding round of $11.9M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Allegro Diagnostics.
- Funding Latest funding round, Debt – Conventional, of $45.0M.
- Acquisition Acquires Decipher.
- Acquisition Acquires HalioDx.
- Acquisition Acquires C2i Genomics.
Competitors of Veracyte
Veracyte has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of Veracyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Veracyte
The website of Veracyte (veracyte.com) receives about 53.7K visits a month and ranks #739,418 among all websites worldwide, #853 in Biotechnology and Pharmaceuticals.
- Monthly visits53.7K
▲ 30.9% vs previous month
- Unique visitors19K
per month
- Global rank#739,418
among all websites
- Category rank#853
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit2.2
- Average visit36 sec
- DevicesDesktop 52% · Mobile 48%
Websites whose visitors overlap most with Veracyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| foundationmedicine.com | 100% | 65K | #611,310 | View details | |
| cardiodx.com | 73% | View details | |||
afirma.com | afirma.com | 73% | #3,611,297 | – | |
thyroidresearchjournal.com | thyroidresearchjournal.com | 51% | – | ||
thyroid.org | thyroid.org | 48% | #184,175 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Veracyte
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Veracyte (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Veracyte
Complete news archive for Veracyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Veracyte
Veracyte was founded in 2008.
Veracyte is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Veracyte is a funded company, having raised a total of $67.9M across 6 funding rounds to date. The company's 1st funding round was a Series A of $11.9M, raised on Jun 2008.
Veracyte has 824 employees.
Annual revenue of Veracyte is $517.14M as on Dec 31, 2025.
Veracyte was founded in 2008 and is headquartered in San Francisco, United States. Genomics-based diagnostics for cancer are developed and offered by the company within the healthcare sector. Products such as the Percepta test are utilized to evaluate lung cancer risk through analysis of bronchial epithelial cells, while the Afirma Thyroid FNA Analysis identifies benign thyroid nodules. Additional tests, including the Envisia classifier for idiopathic pulmonary fibrosis, are under development.
Veracyte's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
Veracyte offers Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier.
Yes, Veracyte is publicly traded on NASDAQ under the ticker symbol VCYT.
Veracyte has made 4 acquisitions, including Allegro Diagnostics, C2i Genomics, and Decipher.
Veracyte has 10 investors. Key investors include Kleiner Perkins, TPG, General Electric, Camber Capital Management, and Broadfin Capital.
Veracyte operates through Veracyte, Inc..